Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE® (trofinetide)
Pipeline
Pipeline
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Aug 27, 2025
Half Yearly Report and Accounts
Aug 25, 2025
First site initiated for Neuren's PMS Phase 3 trial
Aug 12, 2025
Application for quotation of securities - NEU
Aug 08, 2025
Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline
Aug 07, 2025
DAYBUE Q2 2025 net sales US$96.1 million up 14% from Q2 2024
Jul 22, 2025
Change of Director's Interest Notice - J Pilcher
Jul 22, 2025
Application for quotation of securities - NEU
Jul 09, 2025
Notification regarding unquoted securities - NEU
Jun 30, 2025
Application for quotation of securities - NEU
Jun 26, 2025
US patent allowed for NNZ-2591 to treat Pitt Hopkins
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next
